{"id":"NCT02073279","sponsor":"Hoffmann-La Roche","briefTitle":"Efficacy and Safety Study of Satralizumab (SA237) as Monotherapy to Treat Participants With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)","officialTitle":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Satralizumab (SA237) as Monotherapy in Patients With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-08-05","primaryCompletion":"2018-10-12","completion":"2022-01-31","firstPosted":"2014-02-27","resultsPosted":"2020-12-31","lastUpdate":"2023-03-01"},"enrollment":95,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Neuromyelitis Optica (NMO)","NMO Spectrum Disorder (NMOSD)"],"interventions":[{"type":"DRUG","name":"Satralizumab","otherNames":["SA237","RG6168"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Satralizumab","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The objectives of this study are to evaluate the efficacy, safety, pharmacodynamic, pharmacokinetic and immunogenic profiles of satralizumab in participants with NMO and NMOSD.","primaryOutcome":{"measure":"Time to First Protocol-Defined Relapse (TFR) During the Double-Blind (DB) Period","timeFrame":"Up to Week 216","effectByArm":[{"arm":"Placebo, Then Satralizumab","deltaMin":128.3,"sd":null},{"arm":"Satralizumab, Then Satralizumab","deltaMin":null,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0184"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":58,"countries":["United States","Bulgaria","Canada","Croatia","Georgia","Italy","Malaysia","Philippines","Poland","Puerto Rico","Romania","South Korea","Taiwan","Turkey (TÃ¼rkiye)","Ukraine"]},"refs":{"pmids":["40743487","40288333","36724181","36007339","32333898"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":32},"commonTop":["Upper respiratory tract infection","Urinary tract infection","Arthralgia","Headache","Nasopharyngitis"]}}